非侵襲的がん診断の世界市場予測(~2027年)

◆英語タイトル:Non-Invasive Cancer Diagnostics Market Forecasts to 2028 – Global Analysis By Therapeutics (Lung Cancer, Breast Cancer, Solid Tumors and Other Therapeutics), By Technology (Clinical Chemistry, Spectroscopy, Immunoassay and Other Technologies), By End User (Hospitals & Clinics, Ambulatory Care and Other End Users) and Geography

Stratistics MRCが発行した調査報告書(SMR23MR024)◆商品コード:SMR23MR024
◆発行会社(リサーチ会社):Stratistics MRC
◆発行日:2022年11月
◆ページ数:約150
◆レポート形式:英語 / Eメール
◆納品方法:英語
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Global Site LicenseUSD4,150 ⇒換算¥622,500見積依頼/購入/質問フォーム
PDFUSD7,500 ⇒換算¥1,125,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)

❖ レポートの概要 ❖

ストラティスティックスMRC社は、世界の非侵襲的がん診断市場規模が2022年1,142.3億ドルから2028年1,915.7億ドルになり、予測期間中に年平均9.0%で成長すると予測しています。本報告書では、非侵襲的がん診断の世界市場を調査し、エグゼクティブサマリー、序論、市場動向分析、ファイブフォース分析、治療法別(肺がん、乳がん、固形腫瘍、その他)分析、技術別(臨床化学、分光法、免疫測定法、その他)分析、エンドユーザー別(病院&診療所、外来診療、その他)分析、地域別(北米、ヨーロッパ、アジア太平洋、南米、中東・アフリカ)分析、最近の動向、企業情報など、次のように掲載しています。また、企業情報としては、Gen-Probe Inc, Digene Corporation, Quest Diagnostics Inc, Genetics Inc, BIOVIEW Inc, AVIVA Biosciences Corporation, Dr Lal PathLabs Ltd., Laboratory Corporation of America Holdings (LabCorp)などが含まれています。
・エグゼクティブサマリー
・序論
・市場動向分析
・ファイブフォース分析
・世界の非侵襲的がん診断市場規模:治療法別
- 肺がんにおける市場規模
- 乳がんにおける市場規模
- 固形腫瘍における市場規模
- その他治療法における市場規模
・世界の非侵襲的がん診断市場規模:技術別
- 臨床化学技術の市場規模
- 分光法の市場規模
- 免疫測定法の市場規模
- その他技術の市場規模
・世界の非侵襲的がん診断市場規模:エンドユーザー別
- 病院&診療所における市場規模
- 外来診療における市場規模
- その他エンドユーザーにおける市場規模
・世界の非侵襲的がん診断市場規模:地域別
- 北米の非侵襲的がん診断市場規模
- ヨーロッパの非侵襲的がん診断市場規模
- アジア太平洋の非侵襲的がん診断市場規模
- 南米の非侵襲的がん診断市場規模
- 中東・アフリカの非侵襲的がん診断市場規模
・最近の動向
・企業情報

According to Stratistics MRC, the Global Non-Invasive Cancer Diagnostics Market is accounted for $114.23 billion in 2022 and is expected to reach $191.57 billion by 2028 growing at a CAGR of 9.0% during the forecast period. Cancer is a complex medical condition for which no effective treatment has yet been discovered. Non-invasive cancer diagnostics are procedures that identify cancer problems with minimal body incision. Cancer is a disease that is caused by a genetic change in the cells, which leads to uncontrolled growth and the formation of a tumor like structure. Although imaging is the preferred method of cancer detection, it does not allow for genetic access. Biopsies that allow for genetic access, on the other hand, are complex and difficult to perform repeatedly during cancer diagnosis and treatment. Non-invasive cancer diagnostics are becoming more important than traditional cancer diagnosis due to the rise in the occurrence of chronic cancers such as breast cancer and lung cancer.

According to the World Health Organization and the World Cancer Survey, approximately 15 million new cancer cases will be diagnosed each year by 2020, with breast, ovarian, and gastrointestinal cancers being the most common. Because of the traumatic experience and inefficiency of existing procedures, new non-invasive cancer diagnostics with advanced approaches have gained popularity, propelling Non-Invasive cancer diagnostics market growth.

Key players in the market

Some of the key players profiled in the Non-Invasive Cancer Diagnostics Market include Gen-Probe Inc, Digene Corporation, Quest Diagnostics Inc, Genetics Inc, BIOVIEW Inc, AVIVA Biosciences Corporation, Dr Lal PathLabs Ltd., Laboratory Corporation of America Holdings (LabCorp), A&G Pharmaceutical, Roche Holding AG, Affymetrix Inc, Subtle Pharmaceuticals Pvt. Ltd. and Precision Therapeutics.

Key Developments:

In July 2022, Unilabs Sweden partnered with Subtle Medical, a healthcare technology company using artificial intelligence for faster and higher quality MRI, to improve the quality and efficiency of their MRI imaging. Subtle Medical’s SubtleMR would assist radiologists in performing high-quality imaging more efficiently.

In May 2019, Roche Diagnostics introduced the first in vitro diagnostic immunohistochemistry (IHC) assay in 2019 to improve lung cancer diagnosis.

Therapeutics Covered:
• Lung Cancer
• Breast Cancer
• Solid Tumors
• Blood Cancer
• Other Therapeutics

Technologies Covered:
• Clinical Chemistry
• Spectroscopy
• Immunoassay
• Molecular Diagnostics
• Other Technologies

End Users Covered
• Hospitals & Clinics
• Ambulatory Care
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

❖ レポートの目次 ❖

1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Non-Invasive Cancer Diagnostics Market, By Therapeutics
5.1 Introduction
5.2 Lung Cancer
5.3 Breast Cancer
5.4 Solid Tumors
5.5 Blood Cancer
5.6 Other Therapeutics
6 Global Non-Invasive Cancer Diagnostics Market, By Technology
6.1 Introduction
6.2 Clinical Chemistry
6.3 Spectroscopy
6.4 Immunoassay
6.5 Molecular Diagnostics
6.6 Other Technologies
7 Global Non-Invasive Cancer Diagnostics Market, End user
7.1 Introduction
7.2 Hospitals & Clinics
7.3 Ambulatory Care
7.4 Other End Users
8 Global Non-Invasive Cancer Diagnostics Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 Gen-Probe Inc
10.2 Digene Corporation
10.3 Quest Diagnostics Inc
10.4 Genetics Inc
10.5 BIOVIEW Inc
10.6 AVIVA Biosciences Corporation
10.7 Dr Lal PathLabs Ltd.
10.8 Laboratory Corporation of America Holdings (LabCorp)
10.9 A&G Pharmaceutical
10.10 Roche Holding AG
10.11 Affymetrix Inc
10.12 Subtle Pharmaceuticals Pvt. Ltd.
10.13 Precision Therapeutics
List of Tables
Table 1 Global Non-Invasive Cancer Diagnostics Market Outlook, By Region (2020-2028) ($MN)
Table 2 Global Non-Invasive Cancer Diagnostics Market Outlook, By Therapeutics (2020-2028) ($MN)
Table 3 Global Non-Invasive Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) ($MN)
Table 4 Global Non-Invasive Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) ($MN)
Table 5 Global Non-Invasive Cancer Diagnostics Market Outlook, By Solid Tumors (2020-2028) ($MN)
Table 6 Global Non-Invasive Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) ($MN)
Table 7 Global Non-Invasive Cancer Diagnostics Market Outlook, By Other Therapeutics (2020-2028) ($MN)
Table 8 Global Non-Invasive Cancer Diagnostics Market Outlook, By Technology (2020-2028) ($MN)
Table 9 Global Non-Invasive Cancer Diagnostics Market Outlook, By Clinical Chemistry (2020-2028) ($MN)
Table 10 Global Non-Invasive Cancer Diagnostics Market Outlook, By Spectroscopy (2020-2028) ($MN)
Table 11 Global Non-Invasive Cancer Diagnostics Market Outlook, By Immunoassay (2020-2028) ($MN)
Table 12 Global Non-Invasive Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2020-2028) ($MN)
Table 13 Global Non-Invasive Cancer Diagnostics Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 14 Global Non-Invasive Cancer Diagnostics Market Outlook, By End user (2020-2028) ($MN)
Table 15 Global Non-Invasive Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
Table 16 Global Non-Invasive Cancer Diagnostics Market Outlook, By Ambulatory Care (2020-2028) ($MN)
Table 17 Global Non-Invasive Cancer Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
Table 18 North America Non-Invasive Cancer Diagnostics Market Outlook, By Country (2020-2028) ($MN)
Table 19 North America Non-Invasive Cancer Diagnostics Market Outlook, By Therapeutics (2020-2028) ($MN)
Table 20 North America Non-Invasive Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) ($MN)
Table 21 North America Non-Invasive Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) ($MN)
Table 22 North America Non-Invasive Cancer Diagnostics Market Outlook, By Solid Tumors (2020-2028) ($MN)
Table 23 North America Non-Invasive Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) ($MN)
Table 24 North America Non-Invasive Cancer Diagnostics Market Outlook, By Other Therapeutics (2020-2028) ($MN)
Table 25 North America Non-Invasive Cancer Diagnostics Market Outlook, By Technology (2020-2028) ($MN)
Table 26 North America Non-Invasive Cancer Diagnostics Market Outlook, By Clinical Chemistry (2020-2028) ($MN)
Table 27 North America Non-Invasive Cancer Diagnostics Market Outlook, By Spectroscopy (2020-2028) ($MN)
Table 28 North America Non-Invasive Cancer Diagnostics Market Outlook, By Immunoassay (2020-2028) ($MN)
Table 29 North America Non-Invasive Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2020-2028) ($MN)
Table 30 North America Non-Invasive Cancer Diagnostics Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 31 North America Non-Invasive Cancer Diagnostics Market Outlook, By End user (2020-2028) ($MN)
Table 32 North America Non-Invasive Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
Table 33 North America Non-Invasive Cancer Diagnostics Market Outlook, By Ambulatory Care (2020-2028) ($MN)
Table 34 North America Non-Invasive Cancer Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
Table 35 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Country (2020-2028) ($MN)
Table 36 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Therapeutics (2020-2028) ($MN)
Table 37 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) ($MN)
Table 38 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) ($MN)
Table 39 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Solid Tumors (2020-2028) ($MN)
Table 40 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) ($MN)
Table 41 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Other Therapeutics (2020-2028) ($MN)
Table 42 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Technology (2020-2028) ($MN)
Table 43 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Clinical Chemistry (2020-2028) ($MN)
Table 44 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Spectroscopy (2020-2028) ($MN)
Table 45 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Immunoassay (2020-2028) ($MN)
Table 46 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2020-2028) ($MN)
Table 47 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 48 Europe Non-Invasive Cancer Diagnostics Market Outlook, By End user (2020-2028) ($MN)
Table 49 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
Table 50 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Ambulatory Care (2020-2028) ($MN)
Table 51 Europe Non-Invasive Cancer Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
Table 52 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Country (2020-2028) ($MN)
Table 53 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Therapeutics (2020-2028) ($MN)
Table 54 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) ($MN)
Table 55 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) ($MN)
Table 56 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Solid Tumors (2020-2028) ($MN)
Table 57 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) ($MN)
Table 58 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Other Therapeutics (2020-2028) ($MN)
Table 59 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Technology (2020-2028) ($MN)
Table 60 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Clinical Chemistry (2020-2028) ($MN)
Table 61 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Spectroscopy (2020-2028) ($MN)
Table 62 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Immunoassay (2020-2028) ($MN)
Table 63 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2020-2028) ($MN)
Table 64 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 65 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By End user (2020-2028) ($MN)
Table 66 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
Table 67 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Ambulatory Care (2020-2028) ($MN)
Table 68 Asia Pacific Non-Invasive Cancer Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
Table 69 South America Non-Invasive Cancer Diagnostics Market Outlook, By Country (2020-2028) ($MN)
Table 70 South America Non-Invasive Cancer Diagnostics Market Outlook, By Therapeutics (2020-2028) ($MN)
Table 71 South America Non-Invasive Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) ($MN)
Table 72 South America Non-Invasive Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) ($MN)
Table 73 South America Non-Invasive Cancer Diagnostics Market Outlook, By Solid Tumors (2020-2028) ($MN)
Table 74 South America Non-Invasive Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) ($MN)
Table 75 South America Non-Invasive Cancer Diagnostics Market Outlook, By Other Therapeutics (2020-2028) ($MN)
Table 76 South America Non-Invasive Cancer Diagnostics Market Outlook, By Technology (2020-2028) ($MN)
Table 77 South America Non-Invasive Cancer Diagnostics Market Outlook, By Clinical Chemistry (2020-2028) ($MN)
Table 78 South America Non-Invasive Cancer Diagnostics Market Outlook, By Spectroscopy (2020-2028) ($MN)
Table 79 South America Non-Invasive Cancer Diagnostics Market Outlook, By Immunoassay (2020-2028) ($MN)
Table 80 South America Non-Invasive Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2020-2028) ($MN)
Table 81 South America Non-Invasive Cancer Diagnostics Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 82 South America Non-Invasive Cancer Diagnostics Market Outlook, By End user (2020-2028) ($MN)
Table 83 South America Non-Invasive Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
Table 84 South America Non-Invasive Cancer Diagnostics Market Outlook, By Ambulatory Care (2020-2028) ($MN)
Table 85 South America Non-Invasive Cancer Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)
Table 86 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Country (2020-2028) ($MN)
Table 87 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Therapeutics (2020-2028) ($MN)
Table 88 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Lung Cancer (2020-2028) ($MN)
Table 89 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Breast Cancer (2020-2028) ($MN)
Table 90 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Solid Tumors (2020-2028) ($MN)
Table 91 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Blood Cancer (2020-2028) ($MN)
Table 92 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Other Therapeutics (2020-2028) ($MN)
Table 93 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Technology (2020-2028) ($MN)
Table 94 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Clinical Chemistry (2020-2028) ($MN)
Table 95 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Spectroscopy (2020-2028) ($MN)
Table 96 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Immunoassay (2020-2028) ($MN)
Table 97 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2020-2028) ($MN)
Table 98 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Other Technologies (2020-2028) ($MN)
Table 99 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By End user (2020-2028) ($MN)
Table 100 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
Table 101 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Ambulatory Care (2020-2028) ($MN)
Table 102 Middle East & Africa Non-Invasive Cancer Diagnostics Market Outlook, By Other End Users (2020-2028) ($MN)



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 非侵襲的がん診断の世界市場予測(~2027年)(Non-Invasive Cancer Diagnostics Market Forecasts to 2028 – Global Analysis By Therapeutics (Lung Cancer, Breast Cancer, Solid Tumors and Other Therapeutics), By Technology (Clinical Chemistry, Spectroscopy, Immunoassay and Other Technologies), By End User (Hospitals & Clinics, Ambulatory Care and Other End Users) and Geography)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆